Malek, E., Kansagra, A., Costa, L., Usmani, S. Z., Vij, R., Kumar, S., … Liedtke, M. (2021). P-201: Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma. In Clinical Lymphoma Myeloma and Leukemia (Vol. 21, pp. S148–S149). Elsevier BV. https://doi.org/10.1016/s2152-2650(21)02328-4

Malek, Ehsan, Ankit Kansagra, Luciano Costa, Saad Z. Usmani, Ravi Vij, Shaji Kumar, Kelly Godby, et al. “P-201: Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma.” In Clinical Lymphoma Myeloma and Leukemia, 21:S148–49. Elsevier BV, 2021. https://doi.org/10.1016/s2152-2650(21)02328-4.

Malek E, Kansagra A, Costa L, Usmani SZ, Vij R, Kumar S, et al. P-201: Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2021. p. S148–9.

Malek, Ehsan, et al. “P-201: Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma.” Clinical Lymphoma Myeloma and Leukemia, vol. 21, Elsevier BV, 2021, pp. S148–49. Crossref, doi:10.1016/s2152-2650(21)02328-4.

Malek E, Kansagra A, Costa L, Usmani SZ, Vij R, Kumar S, Godby K, Bal S, Cornell R, Kang Y, Umyarova E, Giri S, Chhabra S, Callander NS, Hari P, Liedtke M. P-201: Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2021. p. S148–S149.